(+) Q2 '11 Presentation (Clavis Pharma) - Sep 21, 2011 - CP-4126(CO-101) / Clavis; Anticipated enrollment completion of LEAP study, pivotal study in pancreatic cancer in Q1 2012; Anticipated top line data of LEAP study, pivotal study in pancreatic cancer by end of 2012; Anticipated hENT1 biomarker study data in Q4 2011; Anticipated stage two decision of P2 study for second-line refractory pancreatic cancer in Q4 2011; Anticipated final data of P2 study for second-line refractory pancreatic cancer by year end 2012
Anticipated biomarker data • Anticipated enrollment completion • Anticipated P2 trial final data • Anticipated top-line data • None • Oncology • Pancreatic Cancer
|